Key Considerations for Practical Administration of Ketamine in Severe Depression, and Its Use in Community Care in Edmonton, AB, Canada
Carson Chrenek, Jennifer Swainson
Ketamine 2025 DOI: 10.1007/978-1-0716-4599-4_12 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression Esketamine Ketamine |
| Keywords | Iv ketamine Community program Practical considerations Intranasal esketamine Sublingual ketamine At-home treatment |
| Key findings | Creative alternatives to intranasal esketamine and intravenous ketamine, such as sublingual or at-home administration, may improve patient access to treatment for treatment-resistant depression. |
Abstract
Although both intranasal esketamine and intravenous ketamine have proven efficacy and tolerability in treatment-resistant depression (TRD), patient access to these treatments is often limited due to cost, availability, and/or monitoring requirements. This article is intended to provide a synthesis of the current literature with regard to the pharmacologic use of ketamine in TRD and describe its application to clinical programming in Edmonton, AB, Canada. Topics discussed include rationale for maintenance ketamine treatments, monitoring of long-term safety concerns, and alternative options to intranasal esketamine and intravenous ketamine as creative solutions to improve patient access. Considerations for cautious and judicious prescribing of ketamine outside of highly monitored clinical settings are reviewed.
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |
Citations in the library
Cites 27
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Ketamine use: a review Addiction July 21, 2011
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD) Molecular Psychiatry October 3, 2018
- Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis Journal of Affective Disorders September 23, 2020
- Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression The Journal of Clinical Psychiatry September 2, 2014
and 22 more in the library